320-x-100_uti_gold.jpg" alt="Advertisement">
Supriya Lifescience soars on strengthening position in international markets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Supriya Lifescience is currently trading at Rs. 784.95, up by 10.80 points or 1.40% from its previous closing of Rs. 774.15 on the BSE.
The scrip opened at Rs. 780.00 and has touched a high and low of Rs. 803.65 and Rs. 771.05 respectively. So far 37777 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 835.35 on 04-Dec-2024 and a 52 week low of Rs. 268.75 on 11-Dec-2023.
Last one week high and low of the scrip stood at Rs. 835.35 and Rs. 742.60 respectively. The current market cap of the company is Rs. 6289.33 crore.
The promoters holding in the company stood at 68.30%, while Institutions and Non-Institutions held 11.48% and 20.23% respectively.
Supriya Lifescience has achieved two significant milestones, strengthening its position in international markets. The company has acquired approval from Brazil's health authority, ANVISA (Agencia Nacional de Vigilancia Sanitaria), for Esketamine Hydrochloride, which is a major step in growing its product range in Brazil and the rest of LATAM. Supriya Lifescience is the first firm in Brazil to have received regulatory permission for this highly specialised pharmaceutical. Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market. This approval will enable the company to provide state-of-the-art, high-quality healthcare solutions in a market where demand for novel, reasonably priced drugs is growing.
Moreover, the company submitted a ground-breaking patent application for an enhanced, low-cost method of atorvastatin synthesis. This ground-breaking technique makes drugs more affordable for patients by increasing their efficacy while reducing production costs. Global healthcare relies heavily on atorvastatin, a key treatment for controlling cholesterol and preventing cardiovascular disease, and this achievement shows Supriya's dedication to drug cost and raising accessibility.
Supriya Lifescience is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development.
